31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Former head of litigation at Nokia returns to Bird & Bird

18 August 2026 The new partner counts pharmaceuticals and life sciences among his specialisms and previously worked in-house at Sandoz.

Careers

Former USPTO acting director takes the helm at C4IP

17 August 2026 The IP advocacy group has turned to former USPTO acting director Coke Morgan Stewart as it enters what it calls a “new chapter”.

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

More features

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Brown Rudnick lands largest lateral IP team hire in firm history

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

‘Blatant imitation’: Indian court blocks copycat pharma branding

Kirkland & Ellis adds leading barrister in London

Kilpatrick adds tech patent litigator and China expert to Chicago office

Litigator from Brown Rudnick moves firms to chair practice

Copyright compliance in the life sciences industry

More on this story

Editor's picks

Editor's picks

More features